Ionis Pharmaceuticals Enters License Agreement with Ono for Sapablursen

Details

announced that it has entered into a license agreement with Ono Pharmaceutical Co., Ltd. granting Ono exclusive global rights for the development and commercialization of sapablursen, an investigational RNA-targeted medicine for polycythemia vera (PV). Ionis will receive a $280 million upfront payment and has the potential to earn up to $660 million in additional milestone payments based on development and sales targets. Ionis will complete the ongoing Phase 2 study, while Ono will handle further development, regulatory, and commercialization activities. Sapablursen has been granted Fast Track and orphan drug designations by the FDA for PV.

Items reported

Exhibits (1)

About Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing RNA-targeted therapeutics. The primary mission of Ionis is to harness its expertise in antisense oligonucleotide technology to address complex genetic disorders. Ionis is pioneering in the field of RNA-targeted drug discovery, aiming to treat a wide range of diseases, including neurological, cardiovascular, metabolic, and cancer-related conditions. Notably, the company has a robust pipeline of drugs in various stages of development and partnerships with leading pharmaceutical companies to expand the reach and impact of its therapeutic discoveries. As an innovative entity in the biotechnology sector, Ionis Pharmaceuticals plays a significant role in advancing medical treatments that target the underlying genetic causes of diseases, thereby offering new hope and potential solutions to patients worldwide. Its advancements contribute substantially to the growth and evolution of personalized medicine, emphasizing the importance of genetic research in modern healthcare.